Opus Genetics Completes Enrollment in Phase 1/2 Trial for BEST1 Gene Therapy

Event summary

  • Opus Genetics has completed enrollment in Cohort 1 of its Phase 1/2 study for OPGx-BEST1 gene therapy, including participants with both dominant and recessive forms of BEST disease.
  • Five participants have been enrolled, with three having BVMD and two having ARB; the first four have been dosed.
  • Three-month topline results from Cohort 1 are expected in September 2026.
  • Baseline demographics and early efficacy signals were presented at the ARVO Annual Meeting.

The big picture

Opus Genetics' completion of enrollment in Cohort 1 of its Phase 1/2 study for OPGx-BEST1 marks a significant milestone in the development of gene therapies for BEST1-associated inherited retinal diseases. With no approved treatments currently available for these conditions, the success of this trial could position Opus Genetics as a leader in addressing a critical unmet medical need. The upcoming three-month topline data will be crucial in assessing the therapy's potential to restore vision and prevent blindness in affected patients.

What we're watching

Clinical Efficacy
How the three-month topline data from Cohort 1 will impact the perceived efficacy of OPGx-BEST1.
Regulatory Pathway
Whether the positive early signals will accelerate the regulatory approval process for OPGx-BEST1.
Market Positioning
The pace at which Opus Genetics can differentiate itself in the competitive landscape of gene therapies for inherited retinal diseases.